BerandaAMPH • NASDAQ
add
Amphastar Pharmaceuticals Inc
$42,21
Setelah Jam Perdagangan Normal:(0,00%)0,00
$42,21
Tutup: 10 Mei, 20.00.00 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$42,43
Rentang hari
$41,26 - $42,85
Rentang tahun
$38,43 - $67,66
Kapitalisasi pasar
2,06 M USD
Volume Rata-Rata
338,78 rb
Rasio P/E
16,27
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2023info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 178,10 jt | 31,91% |
Biaya operasional | 42,16 jt | 26,47% |
Laba bersih | 36,17 jt | 6,65% |
Margin laba bersih | 20,31 | -19,15% |
Penghasilan per saham | 0,88 | 20,55% |
EBITDA | 66,80 jt | 50,95% |
Tarif pajak efektif | 11,44% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2023info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 256,81 jt | 46,11% |
Total aset | 1,51 M | 103,90% |
Total liabilitas | 873,49 jt | 309,46% |
Total ekuitas | 639,42 jt | — |
Saham yang beredar | 48,10 jt | — |
Harga terhadap reservasi | 3,19 | — |
Tingkat pengembalian aset | 8,83% | — |
Pengembalian modal | 10,66% | — |
Arus Kas
Perubahan bersih tunai
| (USD) | Des 2023info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 36,17 jt | 6,65% |
Kas dari operasi | 23,86 jt | 56,73% |
Tunai dari investasi | -103,05 jt | -44.899,56% |
Tunai dari pembiayaan | -47,08 jt | -191,32% |
Perubahan bersih tunai | -126,51 jt | -10.938,92% |
Arus kas bebas | 15,61 jt | 11,18% |
Tentang
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Didirikan
1996
Kantor pusat
Situs
Karyawan
1.761
